Current State of AffairsIt is pretty clear that the current state of affairs for the company could best be described as being in a state of flux.
This is not meant to be a negative statement, it simply puts everything into perspective as you are dealing with the PGX - YBG initiative that has likely turned other initiatives on their collective heads. Once again, not in a bad way but in a good way.
What this brings into play is that the use of Beta Glucan may be limited to the base business, at least in the intermediate term until the BG Clincal Study can be proven out. Other initiatives may find themselves using different and more efficient polymers that achieve greater results. This is what new discoveries do to the research side of the street. Ceapro has made great strides and continues to ramp up the game as they discover new processes.
Now, what does this do to the "Ceapro Story"? Great question I must say. At this time, only Gilles Gagnon and team, including McMaster, know the answer to that question and justifiablly so. When I spoke to Jenene Thomas yesterday, she indicated that she has no new updates to provide and any question that I asked her was met with disclosure issues. I don't agree with all of them, I think the term "disclosure" used by her is more of an excuse than anything else but I have to respect her stance.
This scenario has very much delayed the "promised" Ceapro PGX Strategy that was due mid-year. I get it, there have been improvments due to discovery and science. This clearly has changed the "Ceapro Story" from where it was a year ago but what this also means is that all the IB's that were presented to in the past are now due for updates whenever that may be. Are some closer to the new story vs others, such as HCW? Another great question. Don't forget that Cosme Ordonez is likely a very interested spectator. However, and for now, the bottom line is that you still have very little speculation coming out of the US in the form of early buying or expectation of certainty in the short to medium term. However, that is not the way that Gilles Gagnon operates. He is looking to solidyfy the results so that certainty can and will be achieved. Are we far a way from that? I don't think so and today's news points further to solidifying the short term.
What all of this points to from the seat that I sit in is that Ceapro IR is pretty much dormant because they have no update or current story to push, I could be wrong but that was the inference that I got yesterday. You have seen a marked deterioration in the US buying or volume so that tells me that Jenene is either on hold or she has been unsuccessful in gaining the ear of the smart money. Once again, I could be wrong but I think we are all left to the same guessing game.
The bottom line? Gilles Gagnon has never been one to be pushed to say something before it is time, no different this time around. However, a news relase can take on many meanings if one wants to read between the lines.
As far as I am concerned, Ceapro has a significant discovery and knows it. The Company is simply trying to process the data and push to the next level which will likely be very substantial, It will happen.